Intravitreal anti-VEGF therapies are the standard of care for retinal conditions, including neovascular age-related macular degeneration and diabetic macular edema. However, injections may be associated with potentially serious adverse events (AEs). In this second episode of a 6-part series, an expert faculty member shares clinical trial and real-world data on these AEs and insights into their prevention and management.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 259 Prospect Plains Rd, Bldg H
Pricing
100% of listed courses are free
265 of 265 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Infectious Disease
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Neurosurgery
- Nuclear Medicine
- Ophthalmology
- Pediatric Hematology-Oncology
- Psychotic Disorders
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Surgical Oncology
- Urological Oncology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 0.25 credits
- Commercial Support
-
ReleasedJul 31, 2026
-
Last day to claim creditAug 1, 2027 10 months left
-
Vindico Medical Education, LLC Advances in Second-Generation Anti-VEGF Therapy for Retinal Disease
-
PRIME Education, Inc. (PRIME®) Beyond Intravitreal Injections: Advancing Retinal Vascular Disease Care With Sustained Delivery Therapies
-
Answers in CME Inc. (AiCME) Bridging Clinical Trial and Real-World Evidence in Retinal Diseases: Updated Strategies With Anti-VEGF Therapies
-
Physicians’ Education Resource (CME Track) Rapid Reviews in Retina(TM): 2026 Updates – Episode 1: nAMD
-
Physicians’ Education Resource (CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension
-
Physicians’ Education Resource (CME Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies
